HT
LRMR icon

Headlands Technologies’s Larimar Therapeutics LRMR Stock Holding History

Headlands Technologies’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,925
Closed -$103K – 881
2026
Q1 		$103K Buy
+22,925
New +$91.6K 0.01% 662

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Headlands Technologies's LRMR Position: Q2 2026 in Review

Headlands Technologies sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 22,925 shares — an estimated $103K sold.

Headlands Technologies first reported a position in LRMR in Q1 2026 and held it in 1 quarter. The position peaked at $103K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Headlands Technologies reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 22,925 Larimar Therapeutics shares in Q2 2026, an estimated $103K.
  • Headlands Technologies first reported a position in Larimar Therapeutics in Q1 2026 and held it in 1 quarter.
  • Headlands Technologies's Larimar Therapeutics position peaked at $103K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.